Alkermes (ALKS) Stock Revenue Jumps While Margins Lose Steam

Alkermes stock slid 4.3% to US$48.33 after its latest earnings, even though the headline story was not a collapse in the business. The real pressure point was profitability. Quarterly net income landed essentially at break even at about US$0.5 million on US$496 million of revenue, a sharp contrast to the richer margins Alkermes reported over the past year.

That margin squeeze is what traders reacted to, not a demand problem. With adjusted EBITDA at US$139.2 million and a heavier research and development bill tied to the orexin pipeline, the market is now questioning how much earnings power Alkermes can convert from its commercial portfolio.

Is Alkermes now a genuine discount after this earnings wobble, or is the stock’s high P/E masking deeper margin pressure and balance sheet risk? See how the current share price lines up against our detailed valuation analysis for Alkermes

Q2 2026 Earnings Summary

• Revenue, Q2 2026 vs. Q2 2025: US$496.0 million vs. US$390.7 million (up about 26.9%)
• Net Income, Q2 2026 vs. Q2 2025: US$0.5 million vs. US$87.1 million (down about 99.4%)
• Basic EPS, Q2 2026 vs. Q2 2025: US$0.00 vs. US$0.53 (down about 99.4%)
• Adjusted EBITDA Margin, Q2 2026: Adjusted EBITDA of US$139.2 million on revenue of US$496.0 million (about 28.1% margin), reflecting Alkermes R&D ramp behind its orexin portfolio

Prefer clean charts instead of another wall of earnings tables and margin figures? See Alkermes' valuation picture presented in a simple visual dashboard in the company report for Alkermes.

Evaluating Alkermes Bull Case: Sleep and Cash Engine

The bullish view says Alkermes can fund a high impact orexin and sleep portfolio from a solid, cash generative psychiatry base. Q2 hits several of those checkpoints. Proprietary product net sales of US$411.7 million, including the first full quarter of LUMRYZ at US$96.6 million and ongoing contribution from VIVITROL, ARISTADA and LYBALVI, support the idea of a diversified commercial engine rather than a single product story.

The sleep franchise milestones also line up with that narrative. LUMRYZ now carries positive Phase 3 data in idiopathic hypersomnia with an sNDA planned by the end of 2026, and alixorexton has progressed into Phase 3 in narcolepsy with long term extension data showing sustained benefits. At the same time, near break even GAAP net income and a heavier R&D bill indicate that funding this orexin push is already compressing margins, even with US$139.2 million of adjusted EBITDA and about US$690 million of cash and investments on hand.

Compare Alkermes internal cash engine with what institutions are pricing in after this post earnings pullback. See the consensus price target analysis for Alkermes to gauge whether Wall Street targets still line up with the bullish sleep and psychiatry thesis.

Alkermes Bear Case: Margin Strain And Execution Bar Still High

The bearish view on Alkermes centers on two linked worries. Earnings power may not keep up with heavier orexin spending, and the core psychiatry and sleep portfolio may be too concentrated to absorb shocks. Q2 goes part way toward that story. Revenue of US$496.0 million and proprietary net sales of US$411.7 million help counter fears of an immediate demand crack. However, GAAP net income at roughly break even and guidance for a full year GAAP net loss of US$95 to 115 million show that the orexin ramp is already pulling reported profitability down.

Several bear milestones also remain unresolved. Revenue is still anchored in a handful of brands, with no new diversification win this quarter. Higher R&D and SG&A guidance and a heavier fair value charge on LUMRYZ contingent consideration support the idea that execution and margin risk are still firmly on the table.

After such a sharp profit squeeze and heavier orexin spending, are margins the only concern or are there deeper fault lines you might be missing? Review the full risk analysis for Alkermes which shows 3 important warning signs.

Stay Ahead With Simply Wall St

Alkermes has just shown how quickly margins can tighten when R&D ramps, which makes timing your entry and exit more important. Register for free with Simply Wall St and add Alkermes to a Watchlist so you can track price against fair value and wait for an entry point that fits your plan. After you own the stock, use the Portfolio Command Center to cut through market noise and focus on the updates that matter for your holdings. Round out your research by tapping into the collective insight of thousands of investors through the Community so you can spot potential catalysts and risks early and stay ahead of the market.

Seeking Alternatives Before The Crowd

Some stocks are already building quiet momentum while others are dropping out of favor. Fresh opportunities rarely stay under the radar for long, so consider acting early to explore them.

• Spot sturdy businesses that can keep funding growth when conditions change by scanning a curated list of solid balance sheet and fundamentals stocks (48 results).
• Consider early AI momentum instead of focusing only on crowded giants by reviewing a focused basket of 64 profitable AI stocks that aren't just burning cash that already generate real earnings.
• Target potential cash flow anchors for a portfolio that still needs income strength by checking a hand picked lineup of 9 dividend fortresses.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com